Skip to main content

Highlights

  1. 1
    Gastroenterology · 2020
    PMID: 32479824PMCID: PMC7256492DOIFirst author93 citations
  2. 2
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2020
    PMID: 33039584PMCID: PMC8026779DOIFirst author57 citations
  3. 3
    Digestive diseases and sciences · 2020
    PMID: 32617771DOISenior author22 citations

Publications

85 publications

Funding

17 grants

Active

5 grants
  • Co-I
    Molecular and clinical characterization of IBD patients naive or refractory to standard of care over time
    Boehringer Ingelheim Pharmaceuticals, Inc. (Germany) · 2023–2028BioPharma Alliance
    BP 231752-01
  • Sub-PI
    Hyperbaric Oxygen Therapy for Ulcerative Colitis Patients Hospitalized for Moderate to Severe Flares: A Phase 3 Multi-Center, Randomized, Double-Blind, Sham-Controlled Trial
    National Institute of Diabetes and Digestive and Kidney Diseases · 2023–2028 · via Northwestern University
    U01DK134321-04
  • Co-I
    Histological Predictors of Recurrence in Crohn's Disease: A Multicenter Study
    Crohn's and Colitis Foundation of America · 2025–2026
    CCFA #1454068
  • PI
    IBD-START
    Crohn's and Colitis Foundation of America · 2025–2026
    CCFA 253416-01
  • Sub-PI
    Utility of Random Biopsies in Inflammatory Bowel Disease
    National Institute of Diabetes and Digestive and Kidney Diseases · 2024–2026 · via University of Pennsylvania
    U01DK138901-02
Completed grants (12)
  • Sub-PI
    CHASE-EIM: Cohort for Healing Arthritis, Skin, and Eye Extra-Intestinal Manifestations
    Crohn's and Colitis Foundation of America · 2022–2025 · via Cleveland Clinic Foundation
    CCF 862881
  • PI
    AGA EMPOWER-IBD: Clinical Effectiveness Factorial Randomization Trial
    University of Pennsylvania · 2024–2025Contract
    UP 251515-01
  • KP
    Real-World Evaluation of Combination Biologic or Small Molecule Therapy Among Patients with Inflammatory Bowel Disease
    Crohn's and Colitis Foundation of America · 2023–2023
    1148765
  • PI
    Advanced Fellowship in Inflammatory Bowel Disease, Jill Roberts Center For IBD
    Takeda Pharmaceutical Company · 2022–2023
    FEL-005969
  • PI
    Weill Cornell Medicine Advanced IBD Fellowship 2021-22
    Janssen Scientific · 2021–2023Fellowship
    JS FS20673
  • PI
    The Impact of Time Restricted Feeding in Crohn's Disease
    Kenneth Rainin Foundation · 2019–2022
    KRF 2019-1435
  • PI
    Advanced Fellowship in Inflammatory Bowel Disease, Jill Roberts Center For IBD, Weill Cornell Medicine
    AbbVie Inc. · 2021–2022Fellowship
    AVI 214545-01
  • PI
    Weill Cornell Advanced Fellowship in Inflammatory Bowel Disease
    Takeda Pharmaceutical Company · 2021–2022
    FEL-001884
  • PI
    Advanced Fellowship in Inflammatory Bowel Disease New York Presbyterian Hospital-Weill Cornell Medicine Weill Cornell Medical College Jill Roberts Center for Inflammatory Bowel Disease
    AbbVie Inc. · 2020–2021
    AI 209494-01
  • PI
    Advanced Fellowship in Inflammatory Bowel Disease New York Presbyterian Hospital-Weill Cornell Medicine Weill Cornell Medical College Jill Roberts Center for Inflammatory Bowel Disease
    Takeda Pharmaceutical Company · 2020–2021
    IBD Grant FEL-61906
  • PI
    Weill Cornell Medical College Advanced Fellowship Training in Inflammatory Bowel Disease
    AbbVie Inc. · 2020–2020Fellowship
    AbbVie INC. #FEL-59794
  • PI
    Weill Cornell Medical College Advanced Fellowship Training in Inflammatory Bowel Disease
    Takeda Pharmaceutical Company · 2019–2020
    TP FEL-59794

Clinical research

24 studies

Active

11 studies
  • PI
    A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants With Inflammatory Bowel Disease
    PHASE2 · Spyre Therapeutics INC · OPEN TO ACCRUAL (as of 2026)
    Ulcerative Colitis; Inflammatory Bowel Diseases; Colitis; Colitis, Ulcerative
    NCT07652294
  • PI
    A Randomized Trial of the Utility of Random Biopsies in Patients With Inflammatory Bowel Disease
    NA · University of Pennsylvania · OPEN TO ACCRUAL (as of 2026)
    Inflammatory Bowel Diseases; Crohn Disease; Ulcerative Colitis
    NCT06560021
  • PI
    Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis
    PHASE2 · Spyre Therapeutics INC · OPEN TO ACCRUAL (as of 2026)
    Ulcerative Colitis; Inflammatory Bowel Diseases; Colitis; Colitis, Ulcerative
    NCT07012395
  • PI
    An Open-Label, Phase 4, Single-Arm, Multicenter Study to Evaluate the Induction of Response and Remission of Vedolizumab Dual Targeted Therapy With Tofacitinib in Adult Patients With Moderately to Severely Active Ulcerative Colitis
    PHASE4 · Takeda Development Center Americas, Inc. · OPEN TO ACCRUAL (as of 2025)
    Ulcerative Colitis
    NCT06095128
  • PI
    Comprehensive Evaluation of COMBination Advanced Therapy to Achieve Treat-To-Target Endpoints Among Inflammatory Bowel Disease Patients with Inadequate Response to Optimized Monotherapy (COMBAT-IBD)
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
  • PI
    Outcomes of Patients with Inflammatory Bowel Disease and Hidradenitis Suppurativa: A multicenter retrospective chart review
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2024)
  • PI
    Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
    NA · University of California, San Diego · OPEN TO ACCRUAL (as of 2023)
    Ulcerative Colitis; Crohn Disease
    NCT05230173
  • PI
    Chase EIM - Cohort for Healing Arthritis, Skin, and Eye Extra-Intestinal Manifestations
    Crohn's & Colitis Foundation of America, Inc. · OPEN TO ACCRUAL (as of 2023)
  • PI
    Prospective Multicenter Trial to Determine the Efficacy and Outcome of the UCRI In-vitro Diagnostics Device to Detect Treatment Response Measured by Endoscopic Healing in Moderate to Severe Ulcerative Colitis Patients Treated With Anti-TNF-a.
    Glycominds, LLC · OPEN TO ACCRUAL (as of 2021)
    Ulcerative Colitis
    NCT04897282
  • PI
    IBD Qorus: Improving the Quality of Care for Adults with Inflammatory Bowel Disease
    Crohn's & Colitis Foundation of America, Inc. · OPEN TO ACCRUAL (as of 2021)
  • PI
    Inflammatory Bowel Diseases Datamart
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2021)
Completed & closed trials (13)
  • PI
    Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial
    PHASE4 · Beth Israel Deaconess Medical Center, Inc. · IRB STUDY CLOSURE (as of 2026)
    Crohn Disease; Ulcerative Colitis; Inflammatory Bowel Diseases
    NCT04835506
  • PI
    Phase 2a, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of ALTB-268 in Subjects With Moderately to Severely Active Ulcerative Colitis Refractory to Biologic Therapy
    PHASE2 · AltruBio, Inc. · CLOSED TO ACCRUAL (as of 2025)
    Ulcerative Colitis
    NCT06109441
  • PI
    VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment Target
    PHASE4 · Alimentiv Inc. · IRB STUDY CLOSURE (as of 2025)
    Colitis, Ulcerative
    NCT04259138
  • PI
    Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas (STOMP-II)
    PHASE2 · Avobis Bio, LLC · IRB STUDY CLOSURE (as of 2025)
    Perianal Fistula; Crohn's Disease
    NCT04847739
  • PI
    Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of VE202 in Patients With Mild-to-Moderate Ulcerative Colitis
    PHASE2 · Vedanta Biosciences, Inc. · IRB STUDY CLOSURE (as of 2025)
    Ulcerative Colitis; Colitis, Ulcerative
    NCT05370885
  • PI
    Phase 2a, Double-Blind, Randomized Adaptive Design, Placebo-Controlled, Parallel Group Study to Evaluate the Safety, Tolerability, Efficacy, PK and Biomarkers with Oral Colon Delivery PL8177 in Adult Subjects with Active Ulcerative Colitis
    PHASE2 · Palatin Technologies, Inc. · IRB STUDY CLOSURE (as of 2025)
    Ulcerative Colitis; Ulcerative Colitis Acute; Ulcerative; Ulcerative Colitis Flare
    NCT05466890
  • PI
    Tracking Sexual Dysfunction Over Time in Patients with Inflammatory Bowel Disease
    New York University · IRB STUDY CLOSURE (as of 2024)
  • PI
    Predicting Crohn?s & Colitis Outcomes in the United States
    PredictImmune Ltd · IRB STUDY CLOSURE (as of 2023)
  • PI
    Education Intervention on Vaccination Adherence Among IBD Patients at Weill Cornell Medical Center
    NA · Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2023)
    Crohn Disease (CD); Ulcerative Colitis (UC); Indeterminate Colitis
    NCT04672161
  • PI
    Pharmacokinetics of Infliximab and Tumor Necrosis Factor Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis
    Robarts Clinical Trials Inc · IRB STUDY CLOSURE (as of 2023)
    Ulcerative Colitis
    NCT03765450
  • PI
    The Impact of Time Restricted Feeding in Crohn's Disease
    NA · Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2022)
    Crohn's Disease (CD)
    NCT04271748
  • PI
    Assessment of clinical and endoscopic scores in post-resection inflammatory bowel disease patients with small intestinal bacterial overgrowth, bile acid malabsorption or fat malabsorption.
    Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2022)
  • PI
    Multi-center, Double-blind, Randomized, Placebo-controlled, Phase IIa Trial to Evaluate Spesolimab (BI 655130) Efficacy in Patients With Fibrostenotic Crohn's Disease
    PHASE2 · Boehringer Ingelheim Pharmaceuticals, Inc. (Germany) · IRB STUDY CLOSURE (as of 2022)
    Fibrostenotic Crohn´s Disease
    NCT05013385

External relationships

Leadership Roles

AbbVie Inc. · Janssen Scientific Affairs, LLC · Pfizer, Inc.

Advisory/Scientific Board Member

Vedanta Biosciences, Inc.

Speaker/Lecturer

AbbVie Inc.

Other Interest

Eli Lilly and Company · Takeda Pharmaceutical Company Limited

Other

AbbVie Inc. · AltruBio, Inc. · Boehringer Ingelheim Pharmaceuticals, Inc. (USA) · Janssen Scientific Affairs, LLC · Palatin Technologies, Inc. · Pfizer, Inc.